On 16 October 2020, Kintor Pharmaceutical Limited (Stock code: 9939, “Kintor Pharmaceutical”) announced that it has entered into a strategic cooperation agreement on biological drug development with Pumis Pharmaceutical Co., Ltd (普米斯生物技术(珠海)有限公司) (“Pumis”).

In the early stage, Kintor Pharmaceutical had been focusing on small molecule drug development. It is now equipped with full industry chain capabilities of comprehensive small drug development and biologics production. After introducing Pfizer ALK-1 antibody global tumors development right, the Company has comprehensively dedicated to building a R&D channel of “Growing from small molecules to large molecules (筑于小分子，发展大分子)”. Pumis focuses on malignant tumors and metabolic diseases, strives for the R&D and industrialization of innovative biological drugs, and highlights the R&D of a new generation dual targeting antibody drug. This cooperation will take the advantages of both parties, mutually foster and expand their R&D strategies of biological drugs, paving the road for further cooperation in the near future.

Dr. Tong Youzhi, the founder, Chairman and CEO of Kintor Pharmaceutical indicated, “Pumis maintains a leading position in terms of experience in the industry. The commencement of cooperation between Kintor Pharmaceutical and Pumis will boost the R&D and expansion of antibody drug for the Company, and is beneficial to the exploration of more comprehensive treatments during the clinical stage, while positively expanding into a new phase which enables the thriving for both small and large molecules of Kintor Pharmaceutical.”

Mr. Liu Xiaolin, the founder and Chairman of Pumis expressed, ”We are very delighted to have entered into the strategic cooperation agreement with Kintor Pharmaceutical, thank you Kintor Pharmaceutical for their confidence and recognition to our innovative drugs, R&D team as well as technology platform. We will explore the development and clinical strategies of biological drugs with Kintor Pharmaceutical in order to identify better solutions.”

About Kintor Pharmaceutical Limited

Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs, and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. The Company, after years of development, centered upon androgen receptor (AR) related diseases and researched and developed product portfolios in multiple channels covering cancers with a globally high incidence and illnesses yet to meet their clinical requirements, such as prostate cancer, breast cancer, liver cancer and hair loss. Kintor Pharmaceuticals has prospectively deployed a diversified product pipeline that includes small molecule innovative drugs, bio-innovative drugs and combination therapies, including 5 products that are undergoing clinically researched androgen receptor antagonists, ALK-1 monoclonal antibody, mTOR kinase inhibitors and Hedgehog inhibitors, as well as PD-L1/TGF-β dual-targeting antibody, AR-Degrader and c-Myc inhibitors that are undergoing preclinical research. Globally, the Company has more than 60 patents obtained or under review, many of which are listed as the “Major New Drugs Discovery” in National 12th and 13th Five-Year Plans. On 22 May 2020, the Company was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK. Visit http://www.kintor.com.cn for more information.

About Pumis Pharmaceutical Co., Ltd

Pumis was incorporated in July 2018 with a registered capital of USD25 million. Pumis has carried on its start-up vision “Lighting up the innovative fire and reaching a healthy life (点亮创新火种，成就健康人生)”, focusing on malignant tumors and metabolic diseases while dedicating to the R&D and industrialization of the national category I innovative biological drugs, prioritizing the R&D of a new generation dual targeting antibody drug. Since the establishment of Pumis, three rounds of financing have been completed. Meanwhile, it entered into a cooperation agreement with Zhuhai Gaoxin District Government and received several supporting measures from the Gaoxin District Government as a result, while being recognized as Zhuhai Unicorn Enterprise (potential enterprise) (珠海独角兽企业(潜力企业)). Pumis is now pushing on over ten national category I biological new drug projects which includes monoclonal antibody and bispecific antibody. In the next three to five years, the focus will be conducting R&D on a bispecific antibody new drug based on the new generation of tumor immune treatments. Concurrently, Pumis has built core technology platforms for different sectors, including discovery of antibodies, antibody construction renovation, target discovery, pre-clinical and CMC research, which could support an effective and high-quality completion of the antibody new drug project, from the discovery of antibody to clinical reporting. Please visit our Company’s website: www.biotheus.com